A 9-month posttransplantation course of an allogeneic stem-cell transplant recipient (human
cytomegalovirus [HCMV] serostatus, donor positive/recipient negative), in whom ganciclovir …

Background. The emergence of a ganciclovir (GCV)-resistant human cytomegalovirus
(HCMV) strain in a heart transplant recipient (HTR) coinfected by multiple HCMV strains was …

Fifty allogeneic stem cell transplant recipients were enrolled in a prospective
cytomegalovirus pp65 antigenemia-guided preemptive therapy trial. Among these, 10 of 34 …

Background: Emergence of human cytomegalovirus (HCMV) resistance to ganciclovir in
solid-organ transplant recipients has been found to be mostly associated with primary …

Antiviral agents are commonly used for cytomegalovirus (CMV) prophylaxis or therapy after
solid organ transplantation. Until recently, the detection of drug‐resistant CMV in this setting …

We report the case of a lung transplant recipient with progressive cytomegalovirus (CMV)
disease due to a resistant CMV strain emerging under ganciclovir (GCV) therapy. A …

Transplant recipients that have not been previously exposed to the cytomegalovirus (CMV)
are highly susceptible to viral diseases while under immunosuppression therapy. CMV …

Ganciclovir-resistant cytomegalovirus can cause disease and death in transplant recipients.
We describe here a rapid PCR-and sequencing-based assay for ganciclovir resistance that …

Stem-cell transplant recipients are at risk of developing ganciclovir-resistant human
cytomegalovirus (HCMV) infection caused by mutations in the viral UL97 gene. Knowledge …

Background. The incidence and clinical and virologic aspects of ganciclovir-resistant
cytomegalovirus (CMV) disease have not been well-characterized in heart transplant …